Drugs / NALUZOTAN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01281956 | Jan 2011 → Oct 2017 | temporal lobe epilepsy | National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | No outcome recorded |
| Phase 2 | NCT00448292 | Mar → Nov 2007 | major depressive disorder | Epix Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00248183 | Aug 2005 → Jun 2006 | generalized anxiety disorder | Epix Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NALUZOTAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL209821 ↗ |
| Known as | Naluzotan hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL209821 ↗ |
| Known as | NALUZOTAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL209821 ↗ |
| Known as | PRX-00023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00248183 ↗ |
| Action | Activate | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL209821 ↗ |
| Modality | Small molecule | — CHEMBL209821 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL209821 ↗ |